MARKET

CSII

CSII

Cardiovascular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.89
+0.77
+1.79%
Closed 16:00 06/23 EDT
OPEN
44.25
PREV CLOSE
43.12
HIGH
44.25
LOW
42.75
VOLUME
217.13K
TURNOVER
--
52 WEEK HIGH
48.28
52 WEEK LOW
27.70
MARKET CAP
1.76B
P/E (TTM)
-68.3113
1D
5D
1M
3M
1Y
5Y
Cardiovascular Systems, Inc. to Participate at the Raymond James Human Health Innovations Conference
Cardiovascular Systems, Inc. (CSI(R)) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to pre...
Business Wire · 06/02 11:00
BRIEF-Cardiovascular Systems, Inc. Announces U.S. Commercial Launch Of Jade Over-The-Wire Non-Compliant Peripheral Balloon Catheters
reuters.com · 06/01 13:32
Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters
CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES U.S. COMMERCIAL LAUNCH OF JADE OVER-THE-WIRE NON-COMPLIANT PERIPHERAL BALLOON CATHETERS
Business Wire · 06/01 11:00
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
 
Benzinga · 05/25 14:02
Barclays Initiates Coverage on Cardiovascular Systems With Equal Weight Rating, $43 Price Target
MT Newswires · 05/25 08:51
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
Zacks.com · 05/21 14:04
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
Zacks.com · 05/21 12:51
New Study Demonstrates Exceptional Performance With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS) Dual Mode of Action
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world...
Business Wire · 05/20 08:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSII. Analyze the recent business situations of Cardiovascular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CSII stock price target is 45.44 with a high estimate of 50.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 278
Institutional Holdings: 40.19M
% Owned: 100.08%
Shares Outstanding: 40.16M
TypeInstitutionsShares
Increased
57
2.00M
New
13
152.40K
Decreased
78
1.02M
Sold Out
19
208.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.06%
Healthcare Equipment & Supplies
+0.17%
Key Executives
Chairman/President/Chief Executive Officer/Director
Scott Ward
Chief Financial Officer
Jeffrey Points
Chief Operating Officer
Rhonda Robb
Chief Human Resource Officer
Stephen Rempe
Chief Compliance Officer
Sandra Sedo
Vice President - Operations
John Hastings
Vice President
David Whitescarver
General Counsel/Secretary
Alexander Rosenstein
Other
Ryan Egeland
Independent Director
Martha Aronson
Independent Director
Edward Brown
Independent Director
William Cohn
Independent Director
Sachin Jain
Independent Director
Augustine Lawlor
Independent Director
Erik Paulsen
Independent Director
Stephen Stenbeck
Independent Director
Kelvin Womack
No Data
About CSII
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company's coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.

Webull offers kinds of Cardiovascular Systems Inc stock information, including NASDAQ:CSII real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSII stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSII stock methods without spending real money on the virtual paper trading platform.